Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Shares Outstanding (2022 - 2024)

Historic Shares Outstanding for Zentalis Pharmaceuticals (ZNTL) over the last 3 years, with Q1 2024 value amounting to $71.0 million.

  • Zentalis Pharmaceuticals' Shares Outstanding rose 1946.6% to $71.0 million in Q1 2024 from the same period last year, while for Mar 2024 it was $71.0 million, marking a year-over-year increase of 1946.6%. This contributed to the annual value of $70.8 million for FY2023, which is 1937.75% up from last year.
  • Latest data reveals that Zentalis Pharmaceuticals reported Shares Outstanding of $71.0 million as of Q1 2024, which was up 1946.6% from $70.8 million recorded in Q4 2023.
  • In the past 5 years, Zentalis Pharmaceuticals' Shares Outstanding ranged from a high of $71.0 million in Q1 2024 and a low of $45.6 million during Q1 2022
  • For the 3-year period, Zentalis Pharmaceuticals' Shares Outstanding averaged around $62.4 million, with its median value being $59.4 million (2023).
  • Over the last 5 years, Zentalis Pharmaceuticals' Shares Outstanding had its largest YoY gain of 3040.1% in 2023, and its largest YoY loss of 1937.75% in 2023.
  • Quarter analysis of 3 years shows Zentalis Pharmaceuticals' Shares Outstanding stood at $59.3 million in 2022, then rose by 19.38% to $70.8 million in 2023, then rose by 0.35% to $71.0 million in 2024.
  • Its Shares Outstanding was $71.0 million in Q1 2024, compared to $70.8 million in Q4 2023 and $70.6 million in Q3 2023.